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Abstract
Background: Although CD4 T cells are crucial for defense against M.tb, it is still not clear whether the optimal response
against M.tb in fact involves both CD4 and CD8 T cells. To test this, we used a new vaccine strategy that generated a strong
balanced T cell response consisting of both CD4 and CD8 T cells.
Methods and Findings: To compare CD4 and CD8 responses against Ag85B-TB10.4 (H4), H4 was delivered as a subunit
vaccine in cationic liposomes (CAF01), expressed in Ad5 (Ad-H4) or as a heterologous prime boost vaccination. H4/CAF01
induced primarily CD4 T cells and Ad-H4 gave predominantly a CD8 T cell response. In contrast, the heterologous prime
boost combination resulted in augmentation of both the CD4 and CD8 response. The majority (.40%) of the CD4 T cells
induced by the heterologous prime boost protocol were polyfunctional, and expressed IFN-c
+, IL-2
+, and TNF-a
+, whereas
most of the CD8 T cells expressed IFN-c
+ and TNF-a
+ and possessed strong cytotoxic potential. The heterologous prime
boost protocol also gave an increase in protective efficacy against M.tb challenge compared to H4/CAF01 and Ad-H4. Both
the H4 specific CD4 and CD8 T cells were recruited to the site of infection, at the onset of infection. However, compared to
CD8 T cells, CD4 T cells showed more extensive recruitment and were the main T cell subset proliferating at the site of
infection.
Conclusions/Significance: Heterologous prime boost based on H4, produced an additive effect on the priming of CD4 and
CD8 cells and in terms of the protective capacity of the vaccine, and therefore represent an interesting new vaccine strategy
against M.tb. However, CD4 and CD8 T cells respond very differently to live M.tb challenge, in a manner which supports the
consensus that CD4 T cells do play the major role during the early stages of an M.tb infection.
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Introduction
Approximately one-third of the world’s population is latently
infected with Mycobacterium tuberculosis (M.tb), and understanding
the immune mechanisms involved in controlling this chronic
disease is of high priority. The major mechanisms of cell-mediated
immunity include CD4 Th1-cell mediated activation of macro-
phages to destroy intracellular bacterial pathogens, and the central
role of IFN-c in the control of tuberculosis has been clearly
demonstrated by the susceptibility to mycobacterial infections in
mice with a disrupted IFN-c gene and in humans with mutations
in genes involved in the IFN-c and IL-12 pathways [1–4].Unlike
CD4 T cells, which are crucial in the defence against M.tb, the role
of CD8 T cells is not fully resolved. However, numerous studies
have indicated that cytotoxic CD8 T cell-mediated killing of
infected host cells do play a role in the defence against a M.tb
infection [5–10]. Other results in favour of the protective effect of
CD8 T cells come from recent studies, showing that lack of the
RD-1 region in BCG (compared to M.tb) is responsible for the
reduced CD8 T cell response induced by BCG compared to M.tb,
and that re-introducing RD-1 into BCG selectively restored the
CD8 T cell response and importantly also increased the protective
efficacy of the vaccine [11–14]. As a consequence there has
recently been increased focus on the CD8 T cells and several new
vaccine strategies that target these T cells are currently pursued in
many laboratories involved in TB vaccine research. Viral vectors,
such as adeno- or vaccinia virus, trigger a Th1-dominated immune
response, characterized by potent induction of IFN-c, and are also
efficient in inducing a robust CD8 T cell response against their
target antigens. One M.tb vaccine of this type is MVA-85A, a
replication-deficient recombinant vaccinia virus, expressing anti-
gen 85A from M.tb. This vaccine has performed well in animal
models where it induces not only CD8 T cells, but also CD4 T
cells, and significant protection against M.tb. Results from clinical
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5139trials indicate that it is also immunogenic in humans but with a
response almost exclusively composed of CD4 cells [15,16].
Replication-deficient recombinant adenovirus for comparison are
widely accepted as one of the most efficient delivery platforms for
the induction of a CD8 T cell dominated response and adeno
vectors have been evaluated in a number of studies of TB antigens.
The H1 molecule (Ag85B-ESAT-6) expressed in Ad5 was
demonstrated to promote a strong response consisting exclusively
of CD8 cells directed to a few immunodominant epitopes but
unable to protect against TB [17]. Another virally-vectored
vaccine is Aeras-402 Ad35, expressing a fusion of antigen 85A,
antigen 85B, and TB10.4. All three antigens are present in M.tb
and BCG, and all are highly immunogenic. The characterization
of this vaccine in animal models has so far been limited but also
this vaccine is clearly capable of inducing a strong CD8 T cell
responses [18].
The antigens Ag85B and TB10.4 have been extensively
characterized [11,19–22] and a fusion protein consisting of both
Ag85B-TB10.4 adjuvanted with cationic liposomes induced a
strong protection against infection with M.tb [23]. In the present
study we have compared CD4 and CD8 responses against the H4
molecule delivered as a subunit vaccine in cationic liposomes
(CAF01), expressed in Ad5 (Ad-H4) or as a heterologous prime
boost vaccination. Our data demonstrate that the heterologous
prime boost vaccination gives higher levels of both polyfunctional
CD4 T cells, cytotoxic CD8 T cells and protection against M.tb
challenge than Ad-H4 or rH4 on their own. When we monitored
cellular infiltrate in the lung post M.tb challenge in mice vaccinated
by the heterologous prime boost protocol we observed that
whereas high numbers of both H4 specific CD4 and CD8 T cells
were promoted by the vaccine, the CD4 T cells showed
accelerated recruitment to the site of infection compared to
CD8 cells and importantly CD4 cells were the main subset
proliferating in the lung in response to M.tb infection in the
vaccinated animals.
Results
Induction and characterization of the vaccine induced
antigen specific T cell responses
We first compared the immune response promoted by H4
delivered in cationic liposomes (CAF01) expressed in an adeno5
vector or as a hetrologous pirme boost. In particular, we were
interested in whether we could induce both CD4 and CD8 T cells,
as well as in the quantity and phenotype of these cells. CB6F1 mice
were vaccinated once with rH4 followed by a booster Ad-H4
vaccination. Non-vaccinated mice were also included but had no
detectable T cells responses to the vaccine components (data not
shown). One week after the last vaccination, mice were sacrificed
and splenocytes were stimulated in vitro with Ag85B and TB10.4,
and the production of IFN-c, IL-2, and TNF-a by CD4 and CD8
T cells was analyzed by intracellular FACS. We found that all
three vaccines, Ad-H4, rH4, and rH4/Ad-H4, elicited Ag85B
specific CD4 T cells producing all three cytokines (Fig. 1A) and a
significant number of these cells were moreover triple positive (35,
33, and 42%, respectively) (Fig. 1B). However, only rH4 and rH4/
Ad-H4 vaccinated mice contained TNF-a
+IL-2
+ double positive
CD4 T cells (Fig. 1B and D). The triple positive and TNF-a
+IL-2
+
double positive T cell phenotypes generally represent effector
memory- and central memory T cells, respectively [24], indicating
the induction of a more memory like CD4 T cell immune response
by the vaccines rH4 and rH4/Ad-H4, as compared to Ad-H4.
Most importantly, the highest number of antigen specific T cells
was seen in mice vaccinated with rH4/Ad-H4. This vaccine
induced a higher frequency of both IFN-c (1.1%60.3) and TNF-a
(1.3%60.3) producing Ag85B specific CD4 T cells compared to
Ad-H4 and rH4 (p,0.001 and 0.05, respectively) (Fig. 1A), and
the phenotypic profile of the vaccine induced T cell response
reflected the combination of Ad-H4 and rH4 vaccinations since it
contained a high frequency of triple- and double positive memory
CD4 T cells, as well as a significant amount of IFN-c
+TNF-a
+
double positive (and single positive IFN-c
+) effector CD4 T cells
(Fig 1B and D) [24,25]. In general, the level of TB10.4 specific
CD4 T cells was found to be low in all three vaccinated groups,
however, with a significant increase of IFN-c producing CD4 T
cells in the rH4/Ad-H4 vaccinated mice (Fig. 1C). In comparison,
BCG vaccinated mice showed low numbers of Ag85B specific
CD4 T cells, but the highest numbers of TB10.4 specific T cells of
which the major phenotypes were IFN-c
+TNF-a
+IL-2
+ or IFN-
c
+TNF-a
+ expressing CD4 T cells. In terms of CD8 T cells, we
found that only the mice vaccinated with Ad-H4 or rH4/Ad-H4
had detectable numbers of antigen specific CD8 T cells (Fig. 2A
and C), but by combining rH4 and Ad-H4 a larger CD8 T cell
population was observed. We observed an increase in Ag85B
specific IFN-c producing CD8 T cells from 1.1%60.1 in the Ad-
H4 group to 6.8%61.9 in the rH4/Ad-H4 group (p,0.001), and
an increase from 6.2%60.6 to 16%62.3 in the IFN-c producing
CD8 T cells specific for TB10.4 (p,0.001) (Fig 2A and C).
Moreover, when summing up the T cells expressing all
combinations of IFN-c, TNF-a, and IL-2 we found that in the
rH4/Ad-H4 group 6.9% of all CD8 T cells were specific for
Ag85B and 19.6% for TB10.4. Both vaccines induced IFN-
c
+TNF-a
+ double positive CD8 T cells specific for both Ag85B
and TB10.4, and interestingly also a minor, but still detectable,
population of triple positive antigen specific CD8 T cells (Fig. 2B
and D). Consistent with this, stimulation of splenocytes from the
vaccinated mice in vitro for 72 hours (instead of 6 hours in the
FACS analysis) followed by ELISA analysis of IFN-c secretion,
also revealed significantly higher IFN-c production in the rH4/
Ad-H4 vaccine group, although mice from all vaccine groups gave
measurable responses (Fig. 2E). Taken together, we found that
heterologous prime boost based on rH4 and Ad-H4 had a clear
additive effect on the number of vaccine antigen specific CD4 and
CD8 T cells, inducing higher numbers of polyfunctional CD4 and
CD8 T cells compared to rH4 and Ad-H4 vaccinations.
Vaccine induced cytotoxicity
To further characterize the vaccine induced T cells we next
analyzed the cytotoxic potential of the induced CD8 (and CD4) T
cells. We used the recently published MHC class I restricted
epitopes (specific for TB10.43-11 and TB10.420-28) and one MHC
class II restricted epitope (TB10.470-88) [11,21,26]. CFSE labeled
splenocytes from naı ¨ve mice, pulsed (CFSE high) or not pulsed
(CFSE low) with either of the two MHC class I restricted peptides
or the MHC class II restricted epitope from TB10.4, were
adoptively transferred into mice that had been vaccinated with
rH4/Ad-H4 a week before. For comparison we included Ad-H4
and rH4 vaccinated mice. After 4 hours peptide specific lysis of the
transferred cells was determined by FACS analysis of recipient
splenocytes. We observed 78.8%60.2 and 80.6%60.2 specific
killing of the TB10.43-11 loaded target cells (CFSE high) in Ad-H4
and rH4/Ad-H4 mice, respectively, compared to non-loaded
target cells (CFSE low) (p,0.05). The rH4/Ad-H4 mice also
demonstrated strong cytotoxic potential against TB10.420-28
loaded target cells with 70.5%62.3 specific killing, which was
slightly higher than the TB10.420-28 specific killing in Ad-H4 mice
(53.5%66.6, p,0.05) (Fig. 3A and C). In contrast, there was no
killing of target cells loaded with the MHC II restricted epitope
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killing of the transferred target cells (Fig. 3B). Thus, both Ad-H4
and rH4/Ad-H4 induced CD8 T cells with a cytotoxic potential.
The protective efficacy of the vaccine induced T cell
responses
We next analyzed the vaccine induced protection. Vaccinated
CB6F1 mice were challenged six weeks after final vaccination, and
six weeks post challenge, the mice were sacrificed and the bacterial
numbers were determined in the lungs. Ad-H4, rH4, the
hetrologous prime boost combination, non-vaccinated, and BCG
vaccinated mice were included. All the H4 based vaccines induced
significant protection against M.tb challenge but as observed with
the T cell response, combining the two vaccines, rH4 and Ad-H4,
showed an additive effect in terms of protection. Thus, mice
vaccinated with the heterologous prime boost combination of
rH4/Ad-H4 showed a bacterial reduction of 1.2 Log1060.1 CFU,
which was significantly higher than the protection in Ad-H4 and
rH4 vaccinated mice (p,0.01 and p,0.001, respectively). The
BCG-vaccinated mice showed a protection of 1.42 Log1060.1
CFU, which was not significantly different from rH4/Ad-H4
vaccinated mice (Fig. 4A). Interestingly, the CFU levels at six
weeks post infection in the vaccine groups directly correlated with
the ESAT-6 CD4 T cell response (R
2=0.78) (Fig. 4B), in
agreement with previous work indicating that the ESAT-6 specific
response can be used as a predictor for bacterial load [23]. In the
spleen, the highest protection was seen in BCG vaccinated mice,
and in the groups vaccinated with either rH4 or rH4/Ad-H4.
Recruitment of vaccine induced antigen specific CD4 and
CD8 T cells to the site of infection
As we had observed an increase in both CD4 and CD8 T cells
in the group receiving the heterologous prime boost combination
of rH4/Ad-H4, and increased protection, it was important to
compare how the vaccine primed CD4/CD8 T cells responded to
an M.tb infection (in the group where they were both induced, e.g.
the rH4/Ad-H4 group). As controls, non-vaccinated mice were
included. Mice vaccinated with rH4/Ad-H4 (or non-vaccinated)
Figure 1. Cytokine frequencies and phenotypic profiles of specific CD4 T cells in Ad-H4, rH4, or rH4/Ad-H4 vaccinated mice one
week after final vaccination. CB6F1 mice were vaccinated once with Ad-H4, twice with rH4 in cationic liposomes, or once with rH4 in cationic
liposomes followed two weeks later by one Ad-H4 vaccination. Mice were sacrificed one week after the final vaccination and splenocytes were
stimulated with Ag85B or TB10.4 peptides prior to staining with anti-CD4, -CD44, -IFN-c, -IL-2, and –TNF-a. (A and C) Frequencies represent IFN-c, IL-
2, or TNF-a producing CD44
+CD4
+ T cells out of total CD4 T cells specific for Ag85B (A) or TB10.4 (C). Background staining from cells stimulated with
medium alone has been subtracted. Data represent the mean+SEM of a minimum of five mice per group with ***, p,0.001, **, p,0.01, and *, p,0.05
(2-way ANOVA with Bonferroni posttest). (B and D) IFN-c, IL-2, and TNF-a cytokine profiles of Ag85B (B) or TB10.4 (D) specific CD4 T cells shown as
triple, double, or single positive CD4 T cells. The color code for the pies is shown in (E). Dot plots representative of five mice are also shown in (B) and
(D), depicting IFN-c expressed by CD4
+CD44
+ cells after stimulation with Ag85B (B) or TB10.4 (D).
doi:10.1371/journal.pone.0005139.g001
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and two weeks after infection the mice were sacrificed. The two
weeks post infection time point was chosen since the majority of
cells in the lung at that time point are recalled T cells and not yet
newly infection-primed T cells (Non vaccinated showed ,1%
CD8 Ag85B or TB10.4 specific T cells and ,0.2% CD4 T cells)
[23], which enabled us to measure recruitment of the pre-existing
CD4 and CD8 T cells. Lung lymphocytes were stimulated in vitro
with Ag85B and TB10.4, and expression of IFN-c, IL-2, and
TNF-a in the CD4 and CD8 T cell subsets was analyzed by
intracellular FACS. Two weeks post infection we observed a
significant higher proportion of Ag85B and in particular of
TB10.4 specific CD4 T cells in the lungs in the rH4/Ad-H4 group
when compared to the non-vaccinated group (p,0.01) (Fig. 5A
and C). There were also increased levels of CD8 T cells in the
lungs of rH4/Ad-H4 vaccinated mice, in particular of the IFN-c
+
TNF-a
+ effector phenotype (Fig. 5B and D) [24,25]. Of all CD8 T
cells 13.8% were specific for TB10.4 and 2.4% for Ag85B in the
vaccinated group, and the numbers for CD4 T cells were 8.0%
and 4.8%, respectively (Table 1). Thus, both CD4 and CD8 T
cells were recruited to the lungs. Importantly, the CD8 T cells
induced in the non-vaccinated mice showed a much higher
frequency of single positive T cells, as compared to the vaccinated
group, indicating the induction of terminally differentiated T cells
Figure 2. Cytokine frequencies and phenotypic profiles of specific CD8 T cells in Ad-H4, rH4, or rH4/Ad-H4 vaccinated mice one
week after final vaccination. CB6F1 mice were vaccinated once with Ad-H4, twice with rH4 in cationic liposomes, or once with rH4 in cationic
liposomes followed two weeks later by one Ad-H4 vaccination. Mice were sacrificed one week after the final vaccination and splenocytes were
stimulated with Ag85B or TB10.4 peptides prior to staining with anti-CD8, -CD44, -IFN-c, -IL-2, and –TNF-a. (A and C) Frequencies represent IFN-c, IL-
2, or TNF-a producing CD44
+CD8
+ T cells out of total CD8 T cells specific for Ag85B (A) or TB10.4 (C). Background staining from cells stimulated with
medium alone has been subtracted. Data represent the mean+SEM of a minimum of five mice per group with ***, p,0.001, **, p,0.01, and *, p,0.05
(2-way ANOVA with Bonferroni posttest). (B and D) IFN-c, IL-2, and TNF-a cytokine profiles of Ag85B (B) or TB10.4 (D) specific CD8 T cells shown as
triple, double, or single positive CD8 T cells. The color code for the pies is the same as shown in Fig. 1E. Dot plots, representative of five mice, are also
shown in (B) and (D), depicting IFN-c expressed by CD44
+CD8
+ cells after stimulation with Ag85B (B) or TB10.4 (D). (E) Cells were stimulated with
Ag85B or TB10.4 in vitro for 72 hours and IFN-c levels in supernatants were assessed by ELISA. Data represent the mean+SEM of a minimum of five
mice per group with ***, p,0.001, ** and p,0.01 compared with non-vaccinated group, unless otherwise indicated (2-way ANOVA with Bonferroni
posttest).
doi:10.1371/journal.pone.0005139.g002
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Ad-H4 group more than 50% of all the cytokine producing CD4 T
cells had a more memory-like phenotype (IFN-c
+IL-2
+TNF-a
+,
IL-2
+TNF-a
+ or IL-2
+) [24,25], in comparison with only 10–20%
of all the CD8 T cells (Table 1).
To analyze whether there was a more extensive recruitment, or
expansion, of CD4 versus CD8 T cells, we next quantified the cell
proportions of Ag85B and TB10.4 specific CD4 or CD8 T cells
before and after infection. To determine the numbers of the
antigen specific cells, all the subpopulations were added to give the
total number of T cells expressing any combination of IFN-c,
TNF-a, and IL-2 (Table 1). Pre-infection (two weeks pre-infection)
we observed equal amounts of Ag85B specific CD4 and CD8 T
cells in the vaccinated group in the spleen (Fig. 6A). However, 2
weeks post infection there were 2K times more Ag85B CD4 T
cells than CD8 T cells in the lungs (Fig. 6C and E). As for TB10.4
specific T cells, around 50 times more TB10.4 specific CD8 T cells
were observed pre-infection in the spleen than CD4 T cells
(TB10.4 CD4/CD8 ratio of 0.025) (Fig. 6B). However, after
infection we found almost the same numbers of TB10.4 CD4 and
CD8 T cells in the lungs (CD4/CD8 ratio of 0.80) (Fig. 6D and F).
This demonstrated that the CD4 T cells in both the Ag85B and
TB10.4 pool of T cells were initially recruited/expanded more
than the CD8 T cells, even though both cell types were clearly
recruited to the lung at the onset of the infection.
The proliferative capacity of the recruited T cells at the
site of infection
Since CD4 T cells were preferentially recruited to the infection
site, we next evaluated if these infiltrating CD4 T cells were the
result of an increased turn-over rate of CD4 versus CD8 T cells.
The vaccinated and challenged mice were given BrdU in the
drinking water three days before sacrifice to measure the degree of
proliferation of CD4 and CD8 T cells at two weeks post infection.
Of all CD4 T cells 31.5%67.3 had incorporated BrdU, whereas
this number was 11.3%61.3 (p,0.05) for CD8 T cells (Fig. 7A).
Stimulation with TB10.4 or Ag85B followed by gating on the IFN-
c positive antigen specific T cells showed that also for antigen
specific T cells the CD4 T cell population showed the highest
proliferation (Fig. 7B and C). Gating on all combinations of T cell
subtypes expressing one or more of the cytokines IFN-c/IL-2/
TNF-a clearly demonstrated that the majority of proliferating
CD4 cells were cytokine expressing, in contrast to the non-
cytokine producing CD4 T cell population, which did not
proliferate (IFN-c
2IL-2
2TNF-a
2, Fig. 7D). In contrast, for the
Figure 3. Functional characterization of the vaccine induced T cells. The specific lysis of TB10.43-11, TB10.420-28, and TB10.470-88 loaded cells
were determined in an in vivo cytotoxicity assay. Unloaded (CFSE
low) and TB10.43-11, TB10.420-28, or TB10.470-88 (CFSE
high) loaded splenocytes from
naı ¨ve mice were transferred into Ad-H4 (A), rH4 (B), or rH4/Ad-H4 (C) vaccinated mice. (A–C) The amount of splenocytes killed in vivo by cytotoxic T
cells specific for either of the TB10.4 target peptides was observed as a reduction in the CFSE
high population Percent specific lysis was calculated and
is shown in the far right graphs. Non-specific cytotoxicity from non-vaccinated mice has been subtracted (Non-specific killing in non-vaccinated mice
of either CFSEhigh or CFSElow cells were from 5–15%).
doi:10.1371/journal.pone.0005139.g003
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cells were non-proliferating (Fig. 7E). Moreover, when looking at
the frequency of cytokine producing CD4 T cells, we found a clear
tendency towards higher IFN-c, IL-2, and TNF-a production by
the BrdU
+ CD4 T cells compared to the BrdU
2 CD4 T cell
population (Fig. 7D). This tendency was less pronounced, however
still present, in the cytokine producing antigen specific CD8 T cells
(Fig. 7E). In conclusion, both the vaccine induced CD4 and CD8
T cells undergo cell division and were recruited to the site of
infection, at the onset of the infection. However, the CD4 T cells
showed a higher frequency of memory-like phenotypes, were
recruited to the lungs at a higher rate, and proliferated more than
CD8 T cells.
Discussion
CD4 T cells are crucial for defense against M.tb. However, it is
still not clear whether the optimal response against infection with
M.tb in fact involves both CD4 and CD8 T cells and if these
subsets play a role in distinct and different stages of the infection
[27]. In the present study we therefore compared the well
characterized vaccine fusion molecule rH4 (Ag85B-TB10.4)
delivered either as a subunit vaccine in cationic liposomes (rH4/
CAF01) expressed in an adeno5 vector (ad-H4) or as a
heterologous prime boost combination. We clearly show that
rH4/CAF01 induces primarily CD4 T cells, and Ad-H4 CD8 T
cells, but the heterologous prime boost combination induces both
CD4 and CD8 T cells.
Although CD8 T cells are a significant part of the immune
response induced by the natural infection, the role of CD8 T cells
in the defense against M.tb is not fully resolved. Lately, several
vaccine strategies have made use of viral vectors to deliver the
vaccine antigens, and to induce vaccine specific CD8 T cells [28–
30]. These studies all point to a protective role for CD8 T cells,
even though in most of these studies CD4 T cells were also primed.
Studies using MVA as delivery of the vaccine antigens have
indicated that this vector is particularly efficient when used as a
booster vaccine, and boosting of both CD4 and CD8 T cells have
been observed [15,31]. Likewise, adenoviral vectors have been
found to serve as efficient boosters of existing immune responses.
Thus, adenovirus expressing Ag85A was able to boost BCG
immunity, which in turn increased the protection against M.tb
[32]. As with MVA, adenovirus boosted both the CD4 and CD8 T
cell activity, and priming of both these subsets was also observed
when following immunization with adenovirus expressing myco-
bacterial antigens [18,29,33]. In other recent studies, in which
only CD8 T cells to immunodominant antigens (such as ESAT-6
or TB10.4) were induced, only minor or no protection was
observed [17,21], indicating that the contribution of CD8 T cells
to protection may depend on, or increase inthe presence of, an
ongoing CD4 T cell response. This is in line with studies showing
that both CD8 T cell memory induction and maintenance can be
influenced by CD4 T cells [34–40]. However, it should be
mentioned that in two studies using vaccination with a DNA
vaccine encoding CFP10, or a mix of several TB proteins, the
vaccine induced CD8 T cells were shown to induce protection,
demonstrating that in some instances CD8 T cells do provide
Figure 4. The protective efficacy and correlation of protection
with infection driven immune response in the vaccinated and
challenged mice. (A and B) Protection in vaccinated mice (expressed
as Log10 CFU reduction) compared to unvaccinated and BCG vaccinated
controls challenged by the aerosol route with virulent M.tb. six weeks
after the final vaccination. Six weeks post-challenge, the mice were
sacrificed and the bacterial burden (CFU) was measured in the lung or
spleen. Data represent the mean+SEM of a minimum of five mice per
group in two individual experiments with ***, p,0.001 and **, p,0.01
(2-way ANOVA with Bonferroni posttest). (C) Relation between
protection (CFU) and ESAT-6 specific IFN-c producing CD4 T cells is
shown as a fitted regression line with the correlation coefficient (R
2). Six
weeks post challenge, the mice were sacrificed and the lung cells were
stimulated with ESAT-6 overlapping peptides prior to staining with anti-
CD4, -CD44, and –IFN-c. Frequencies represent IFN-c producing ESAT-6
specific CD44
+CD4
+ T cells out of total CD4 T cells. Background staining
from cells stimulated with medium alone has been subtracted. Data
represent the mean of +SEM of a minimum of five mice per group in
two individual experiments.
doi:10.1371/journal.pone.0005139.g004
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strictly dependent upon simultaneous induction of CD4 T cells
[5,41].
In the present study we wanted to study the potential of a
heterologous prime boost vaccine strategy that induce both CD4
and CD8 T cells, and to compare the phenotype of vaccine
primed CD4 and CD8 T cells, as well as the recruitment and
proliferation of these cells following infection with M.tb. We
combined vaccination of a CD4 T cell inducer, rH4/CAF01, with
a strong CD8 T cell inducer, Ad-H4. Mice vaccinated with the
rH4/Ad-H4 combination showed an increase in CD4 T cell
activity indicating that rH4 primed CD4 T cells can be boosted by
Ad-H4 immunization. Compared to Ad-H4, rH4/Ad-H4 also
induced significant higher numbers of cytokine producing CD8 T
cells. In the rH4/Ad-H4 group approximately 27% of all CD8 T
cells were specific for the vaccine antigens, with 7% being specific
for Ag85B and 20% for TB10.4. Most of these (45–80%) CD8 T
cells expressed IFN-c and TNF-a (Fig. 1 and 2) which suggests an
effector phenotype. This clearly demonstrated that combining rH4
and Ad-H4 had a strong additive effect on priming for both the
CD4 and CD8 T cell response. It can be speculated that the
boosting of the CD4 T cells, which occurred in parallel with the
priming of CD8 T cells, provided increased CD4 help for the CD8
T cells, thereby further promoting the activation and expansion of
these cells. We also observed a slightly increased cytolytic function
of the CD8 T cells in the rH4/Ad-H4 group, in particular against
TB10.4 20-28 loaded target cells (17% increase in the specific killing
of these cells in the rH4/Ad-H4 group cpmpared to the Ad-H4
group) (Fig. 3). This may be due to increased CD8 T cell numbers,
increased cytolytic capacity of the individual T cells, or that the
CD8 T cells in the rH4/Ad-H4 group were primed in the
presence of CD4 T cells, which have been suggested to increase
both the persistence of CD8 T cells and the ability of the CD8 cells
to respond to a secondary encounter with their antigen [34–38].
In terms of protection against infection with M.tb, we found, as
observed with the numbers of vaccine specific T cells (Fig. 1 and
2), that combining the two vaccine strategies also had a significant
additive effect in the lung. Thus, mice vaccinated with rH4/Ad-
H4 showed a protection of 1.2 Log1060.1 CFU, which was
significantly higher than the protection observed in the Ad-H4 and
rH4 mice (Fig. 4A) and not significantly different from that
observed in BCG vaccinated mice. The Ad-H4 group showed a
protection of approximately 0.4 Log10 CFU, which is in
agreement with a recent study using Ad-35-Ag85A-Ag85B-
TB10.4 [18]. Interestingly, in the spleen, the lowest protection
was observed in the Ad-H4 group, which may indicate that
prevention of dissemination from the lung to the spleen require
CD4 T cells more than CD8 T cells (Fig. 4B).
In the rH4/Ad-H4 group two weeks after infection we observed
that 14% of all CD8 T cells in the lungs were specific for TB10.4
Figure 5. Cytokine frequencies and phenotypic profiles of specific CD4 and CD8 T cells in non-vaccinated or rH4/Ad-H4 vaccinated
mice two weeks after challenge. CB6F1 mice were vaccinated once with rH4 in cationic liposomes followed two weeks later by one Ad-H4
vaccination, and challenged by the aerosol route with virulent M.tb six weeks after the final vaccination. Two weeks after challenge the mice were
sacrificed and lung lymphocytes were stimulated with Ag85B or TB10.4 peptides prior to staining with anti-CD4, -CD8, -CD44, -IFN-c, -IL-2, and –TNF-
a. Frequencies represent IFN-c, IL-2, or TNF-a producing CD44
+CD4
+ or CD44
+CD8
+ T cells specific for Ag85B (A and B) or TB10.4 (C and D).
Background staining from cells stimulated with medium alone has been subtracted. Data represent the mean+SEM of four mice per group with **,
p,0.01 (2-way ANOVA with Bonferroni posttest). IFN-c, IL-2, and TNF-a cytokine profiles of Ag85B or TB10.4 specific CD4 and CD8 T cells are shown in
pies as triple, double, or single positive CD4 or CD8 T cells. The color code for the pies is the same as shown in Fig. 1E.
doi:10.1371/journal.pone.0005139.g005
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indeed processed and presented in the lungs at the very onset of
infection, and that CD8 T cells primed by Ad5 vector delivery, as
well as the CD4 T cells, were recruited to the site of infection (pre-
infection the numbers in the lung were less than 0.1%, data not
shown) (Fig. 5). For both the CD4 and CD8 T cell subsets we
observed more polyfunctional cells (IFN-c
+TNF-a
+ or IFN-
c
+TNF-a
+IL-2
+) in the rH4/Ad-H4 group following M.tb
challenge compared non-vaccinated mice. This could indicate
that this vaccination strategy resulted in a pool of polyfunctional T
cells that was maintained after challenge, whereas the natural
infection of unprimed mice tended to drive the activated T cells
toward a state of terminal differentiation (IFN-c
+) (Fig. 5) [25].
Interestingly, in the rH4/Ad-H4 vaccinated mice, we noted
important differences between the CD4 and CD8 T cell recall
responses. Thus, although we observed strong, local CD8 T cell
memory, as measured by total CD8 T cell numbers, CD4 T cells
preferentially accumulated (due to recruitment and/or expansion)
at the site of infection (Fig. 6). In line with this, CD4 T cells with
proliferative capacity showed higher accumulation at the site of
infection than CD8 T cells two weeks post infection (although we
can exclude that this bias in CD4 proliferation may in part reflect
a bias inherent in the CD4 prime/boost mechanism). This was
observed by analyzing the total pool of CD4 T cells, and also when
studying TB10.4 and Ag85B antigen specific T cells (Fig. 7).
Moreover, as for the phenotype of the proliferating cells, the
majority of the cytokine (any combination of IFN-c, TNF-a or IL-
2) producing CD4 T cells belonged to the proliferating CD4 T cell
population, in contrast to the cytokine producing CD8 T cells that
where mainly non-proliferating (Fig. 7). Taken together, these data
revealed that although both CD4 and CD8 T cells were primed
through vaccination, there was an increased recruitment and
proliferation of the CD4 T cells as compared to the CD8 T cells
suggesting that this subset may be primarily involved in the recall
response that results in early control of bacterial replication in
vaccinated mice, and that increasing the CD4 T cell numbers in
this stage of the infection is important. We are presently testing H4
in new adjuvants specifically selected for their ability to induce a
strong CD4 T cell response.
In conclusion, heterologous prime boost based on H4, produced
an additive effect on the priming of CD4 and CD8 cells and in terms
of the protective capacity of the vaccine, and therefore represent an
interesting vaccine strategy against M.tb. However, compared to
CD8 T cells, antigen specific CD4 cells were more polyfunctional,
recruited at a higher rate, and proliferated more following infection
with M.tb, indicating that although both CD4 and CD8 epitopes are
clearlypresentedat the veryonset ofinfection,CD4and CD8 T cells
respond very differently to live infection, in a manner which support
the consensus that CD4 T cells play the major role during the early
stages of an M.tb infection.
Materials and Methods
Ethics Statement
The handling of mice were conducted in accordance with the
regulations set forward by the Danish Ministry of Justice and
animal protection committees by Danish Animal Experiments
Inspectorate, and in compliance with European Community
Directive 86/609 and the U.S. Association for Laboratory Animal
Care recommendations for the care and use of laboratory animals.
Animals
Studies were performed with six-eight week-old female CB6F1
(C57BL/66BALB/c) mice from Harland Netherlands. Non-infected
mice were housed in cages in appropriate animal facilities at Statens
Serum Institut or at the Panum Institute, University of Copenhagen.
Infected animals were housed in cages contained within laminar flow
safety enclosures (Scantainer from Scanbur, Denmark) in a separate
biosafety level 3 facility at Statens Serum Institut. All mice were fed
radiation sterilized 2016 Global Rodent Maintenance diet (Harlan,
Scandinavia) and water ad libitum. All animals were allowed a one-
week rest before initiation of the experiments.
Table 1. Frequency of T cell subsets.
T cells (%)*** Two weeks pre-infection* Two weeks post Infection**
Ag85B TB10.4 Ag85B TB10.4
CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8
IFN-c
+ IL-2
+ TNF-a
+ 0.44 0.06 0.01 0.04 0.40 0.04 0.67 0.18
IFN-c
+ IL-2
+ TNF-a
2 0.00 0.01 0.00 0.02 0.01 0.00 0.03 0.00
IFN-c
+ IL-2
2 TNF-a
+ 0.34 1.13 0.03 3.29 1.99 1.68 3.56 10.99
IFN-c
+ IL-2
2 TNF-a
2 0.03 0.81 0.00 2.11 0.11 0.27 0.10 1.46
IFN-c
2 IL-2
+ TNF-a
+ 0.37 0.03 0.01 0.96 0.30 0.00 0.56 0.02
IFN-c
2 IL-2
+ TNF-a
2 0.00 0.00 0.00 0.00 0.00 0.11 0.00 0.32
IFN-c
2 IL-2
2 TNF-a
+ 0.51 0.66 0.10 0.64 2.03 0.25 3.10 0.89
In total 1.69 2.69 0.15 7.05 4.84 2.35 8.03 13.85
Two weeks pre-infection* Two weeks post Infection**
CD4 T cell (%)*** 15.1 25.1
CD8 T cell (%) 18.0 19.4
Frequency of cytokine producing Ag85B and TB10.4 specific CD4 and CD8 T cells two weeks before and after M.tb challenge, as well as the frequencies of total CD4 and
CD8 T cells, in rH4/Ad-H4 vaccinated mice.
*The frequencies were obtained by FACS analysis on in vitro antigen stimulated splenocyte cultures from vaccinated mice (two weeks before challenge).
**The frequencies were obtained by FACS analysis on in vitro antigen stimulated lung lymphocyte cultures from vaccinated and M.tb challenged mice two weeks after
challenge.
***Background staining from cells stimulated with medium alone has been subtracted.
doi:10.1371/journal.pone.0005139.t001
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PLoS ONE | www.plosone.org 8 April 2009 | Volume 4 | Issue 4 | e5139Figure 6. Recruitment of Ag85B and TB10.4 CD4 and CD8 T cells to the lung. Antigen specific CD4 and CD8 T cells in rH4/Ad-H4 vaccinated
mice were measured two weeks before and after challenge. CB6F1 mice were vaccinated once with rH4 in cationic liposomes followed two weeks
later by one Ad-H4 vaccination, and challenged by the aerosol route with virulent M.tb six weeks after the final vaccination. Two weeks before
challenge and two weeks after challenge mice were sacrificed, and splenocytes and lung lymphocytes, respectively, were stimulated with Ag85B or
TB10.4 peptides prior to staining with anti-CD4, -CD8, -CD44, -IFN-c, -IL-2, and –TNF-a. (A–D) The number of cytokine producing T cells is a total
number of triple, double, and single positive IFN-c, TNF-a, and IL-2 producing antigen specific CD4 or CD8 T cells either per spleen pre-infection (A
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In experiments measuring proliferation, BrdU (0.8 mg/ml) was
added to the drinking water to the mice for three days before
sacrifice.
Bacteria
M.tb Erdman was grown at 37uC in suspension in Sauton
medium (BD Pharmingen) enriched with 0.5% sodium pyruvate,
0.5% glucose, and 0.2% Tween 80. All bacteria were stored at
and B) or per lung post infection (C and D). Background staining from cells stimulated with medium alone has been subtracted. Data represent the
mean+SEM of four mice per group with **, p,0.01 (2-way ANOVA with Bonferroni posttest). (E and F) The ratio between Ag85B (E) and TB10.4 (F)
specific CD4 and CD8 T cells was calculated from A–D.
doi:10.1371/journal.pone.0005139.g006
Figure 7. The proliferative capacity and frequency of the recruited Ag85B and TB10.4 specific CD4 and CD8 T cells to the lungs.
CB6F1 mice were vaccinated once with rH4 in cationic liposomes followed two weeks later by one Ad-H4 vaccination, and challenged by the aerosol
route with virulent M.tb at week 10. The last three days before killing, BrdU (0.8 mg/ml) was added to the drinking water. Two weeks after challenge,
mice were sacrificed and lung lymphocytes were stimulated with Ag85B or TB10.4 peptides prior to staining with anti-CD4, -CD8, -BrdU, and -IFNc
(A–C). (A) Frequencies represent the percentage of BrdU
+ CD4 or CD8 T cells out of total CD4 or CD8 T cells. Data represent the mean of +SEM of
four mice per group with *, p,0.05 (Unpaired t-test, two-tailed). Dot plots, representative of four mice, are also shown depicting BrdU
+ CD4 or CD8 T
cells. (B and C) Frequencies represent the percentage of BrdU
+ CD4 or CD8 T cells out of total IFN-c
+ CD4 or CD8 T cells specific for either Ag85B (B)
or TB10.4 (C). Data represent the mean+SEM of two mice per group with **, p,0.01 (Unpaired t-test, two-tailed). Background staining from cells
stimulated with medium alone has been subtracted. (D and E) CB6F1 mice were vaccinated once with rH4 in cationic liposomes followed two weeks
later by one Ad-H4 vaccination, and challenged by the aerosol route with virulent M.tb at week 10. The last three days before sacrificing the animals,
BrdU (0.8 mg/ml) was added to the drinking water. Two weeks after challenge mice were sacrificed and lung lymphocytes were stimulated with
TB10.4 peptides prior to staining with anti-CD4, -CD8, -BrdU, -IFN-c, TNF-a, and IL-2. The BrdU histograms represent a normalized overlay of all the
cytokine producing CD4 (D) and CD8 (E) T cells, (IFN-c
+IL-2
+TNF-a
+, IFN-c
+TNF-a
+, IFN-c
+IL-2
+, IFN-c
+, IL-2
+TNF-a
+, IL-2
+, and TNF-a
+) (solid line), and
all the non-cytokine producing CD4 and CD8 T cells (IFN-c
2IL-2
2TNF-a
2) (dashed line), and the percentages shown are the percentages of cytokine
producing or cytokine non-producing T cells out of total T cells. Instead of displaying counts in the FACS histogram overlays, each histogram in the
overlay has been normalized to its maximum counts (‘‘% of MAX’’ counts). Data represent the mean of +SEM of three mice per group. Background
staining from cells stimulated with medium alone has been subtracted.
doi:10.1371/journal.pone.0005139.g007
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8 CFU/ml. Bacteria were
thawed, sonicated, washed, and diluted in phosphate-buffered
saline (PBS) for immunizations and infections. All bacterial work
was performed at the Statens Serum Institut by authorized
personnel.
Construction of recombinant replication-deficient
adenoviral 5 based vaccine Ad-H4
The M.tb fusion protein H4 consisting of the two antigens
Ag85B and TB10.4 was amplified by overlapping PCR from
plasmid template and cloned into a pacCMV-based shuttle
vector. From the shuttle plasmid, human type 5 recombinant
non-replicating adenovirus vectors were produced from homol-
ogous recombination by standard methods [42]. After purifica-
tion, adenoviral stocks were immediately aliquoted and frozen at
280uC in 10% glycerol, and the infectivity of the adenoviral
stocks was determined with Adeno-X Rapid Titer kit (BD
Clontech).
Immunization
Mice immunized with Ad-H4 were anesthetized and injected
once with 2610
7 infectious units (IFU) s.c. in the right hind
footpad. Mice immunized with the Ag85B-TB10.4 fusion protein
(rH4) were immunized twice at two-week intervals s.c. at the base
of the tail with a total volume of 200 ml containing 5 mg rH4
formulated in cationic liposomes (CAF01). For boosting studies,
mice received a single dose of rH4 injected s.c. at the base of the
tail and two weeks later the mice were given one booster
vaccination of Ad-H4 in the right footpad. Non-vaccinated control
mice received NaCl s.c. at the base of the tail, and the BCG
control mice received a single dose of BCG Danish 1331 (2.5610
5
CFU) injected s.c. at the base of the tail.
Experimental infections
When challenged by the aerosol route, the animals were
infected with ,50 CFU of M.tb Erdman/mouse with an
inhalation exposure system (Glas-Col, Indiana, USA). Mice were
challenged eight weeks after the first vaccination and killed either
two weeks post-challenge for immune surveillance or six weeks
post-challenge for bacterial counts. Numbers of bacteria in the
lung were determined by serial three-fold dilutions of individual
whole-organ homogenates in duplicate on 7H11 medium.
Colonies were counted after two-three weeks of incubation at
37uC. Protective efficacies were expressed as log10 bacterial CFU.
Lymphocyte preparation
Splenocytes and lung lymphocytes were obtained by passage of
the organs through a 100 mm nylon cell strainer (BD Pharmingen,
USA) followed by two washing procedures using RPMI 1640.
Cells in each experiment were cultured in sterile microtiter wells
(96-well plates; Nunc, Denmark) containing ,2610
6 cells in
200 ml of RPMI 1640 supplemented with 1% (v/v) premixed
penicillin-streptomycin solution (Invitrogen Life Technologies),
1 mM glutamine, and 5% (v/v) fetal calve serum (FCS) at 37uC/
5% CO2. The lymphocyte cultures were further used for ELISA
and FACS analysis.
Antigens for in vitro stimulation
Synthetic overlapping peptides (9- and 18-mers) covering the
complete primary structure of Ag85B, TB10.4, and ESAT-6 were
synthesized by standard solid-phase methods on a SyRo peptide
synthesizer (MultiSynTech, New England) at the JPT Peptide
Technologies (Berlin, Germany), or at Schafer-N (Copenhagen,
Denmark). Peptides were lyophilized and stored dry at 220uC
until reconstitution in PBS.
IFN-c enzyme-linked immunosorbent assay (ELISA)
Microtiter plates (96 well; Maxisorb; Nunc, Denmark) were
coated with 1 mg/ml monoclonal rat anti-murine IFN-c (clone
R4-6A2; BD Pharmingen). Free binding sites were blocked with
2% (w/v) milk powder in PBS. Culture supernatants were
harvested from lymphocyte cultures after 72 hours of in vitro
antigen stimulation and tested in triplicates. IFN-c was detected
with a 0.1 mg/ml biotin-labeled rat anti-murine antibody (mAb;
clone XMG1.2; BD Pharmingen, USA) and 0.35 mg/ml horse-
radish peroxidase-conjugated streptavidin (Zymed, Invitrogen,
USA). The enzyme reaction was developed with 3.39, 5.59-
tetramethylbenzidine, hydrogen peroxide (TMB plus; Kementec,
Denmark) and stopped with 0.2 M H2SO4. rIFN-c (BD
Pharmingen, USA) was used as a standard. Plates were read at
450 nm with an ELISA-reader and analyzed with KC4 3.03 Rev 4
software.
Flow cytometric analysis
Intracellular cytokine staining procedure: Splenocytes or lung
lymphocytes were stimulated for 1 h with 2 mg/ml antigen at
37uC/5% CO2 and subsequently incubated for 5 h at 37uC with
10 mg/ml brefeldin A (Sigma-Aldrich, USA) at 37uC. The cells
were washed in FACS buffer (PBS containing 0.1% sodium azide
and 1% FCS) before surface staining with rat anti-mouse
antibodies. Cells were washed with FACS buffer before fixation
and permeabilization using the BD Cytofix/Cytoperm
TM (BD,
San Diego, CA, USA) according to the manufacturer’s protocol
followed by intracellular staining. When staining with FITC-anti-
BrdU an extra fixation and permabilisation step, as well as DNAse
treatment, was introduced before the intracellular staining. Cells
were washed and resuspended in formaldehyde solution 4% (w/v)
pH 7.0 (Bie & Berntsen, Denmark) and samples were analyzed on
a six-color BD FACSCanto flow cytometer (BD Biosciences,
USA). Data analysis was done on FlowJo Software ( Tree Star,
Asland, OR, USA). The following antibodies were used for surface
staining: PerCP-Cy.5.5-anti-CD8a (53-6.7), APC-Cy7-anti-CD4
(GK1.5), and FITC-anti-CD44. For intracellular staining the
following antibodies were used: PE-anti-TNF-a, APC-anti-IL-2,
PE-Cy7-anti-IFN-c, and FITC-anti-BrdU. All antibodies were
purchased from BD Pharmingen (San Diego, USA) or eBios-
ciences (San Diego, USA).
In vivo cytotoxicity assessed by adoptive transfer of
CFSE-labeled target cells
Single splenocyte suspensions of CB6F1 mice were obtained by
passage through a fine 100 mm nylon cell strainer (BD Pharmin-
gen, USA). Erythrocytes were depleted by lysis in ammonium
chloride solution, washed in PBS before resuspension in
incomplete RPMI and stained with 5(6)-Carboxyfluorescein
diacetate N-succinimidyl ester (CFSE) (Sigma-Aldrich, San Louis,
USA) at CFSE
high (40 mM) or CFSE
low (4 mM) concentration for
10 min at 37uC. Excess CFSE was quenched with RPMI
containing 10% FCS and subsequently washed in medium
without FCS. Next, CFSE
high labeled cells were pulsed with
TB10.43-11, TB10.420-28, or TB10.474-88 peptides at a concentra-
tion of 10 mg/ml for 1.5 hr at 37uC. After being washed and
resuspended in PBS the CFSE
high and CFSE
low suspensions for
each peptide was mixed at equal volumes. Finally, 10610
6 cells
per target peptide per mouse were given intravenously into naı ¨ve
mice and mice vaccinated one week before. Four hours later,
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removed, homogenized and resuspended in formaldehyde before
acquisition on a BD FACSCanto flowcytometer (BD Biosciences,
USA). To evaluate the frequency of specific lysis, the ratio of
CFSE
high and CFSE
low of infected mice were compared to naı ¨ve
control mice and was calculated using the formula (12(%CFSE-
high cells/%CFSE
low cells)6100%). For the immunized and naı ¨ve
groups two mice were used respectively.
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